(1) 新型抗肿瘤药物研发
(2) 广谱抗冠状病毒药物研发

(1) 国家自然科学基金委员会，青年科学基金项目，22107117，基于环肽的新型溶酶体靶向嵌合体（LYTAC）PD-L1降解剂的设计、合成以及抗肿瘤活性研究，2022/01-2024/12，30万，在研，主持
(2) 中国博士后科学基金会，中国博士后科学基金面上资助，2021M693516，靶向NQO1/NAMPT小分子化合物的设计、合成以及抗肿瘤活性研究，2021/07-2023/06，8万，结题，主持
(3) 江苏省人力资源和社会保障厅，江苏省博士后科研资助计划，2021K218B，靶向NQO1/NAMPT小分子化合物的设计、 合成以及抗非小细胞肺癌活性研究，2021/07-2023/06，5万，结题，主持
(4) 国家自然科学基金委员会，国际(地区)合作与交流项目，82161138005，全新2’-O-甲基转移酶抑制剂:设计、合成及其抗新冠病毒的活性评价，150万/30万，结题，参与，2021/03-2023/02.

1. Wang, K.; Ye, K.; Zhang, X.; Wang, T.; Qi, Z.; Wang, Y.; Jiang, S.*; Zhang, K.*, Dual Nicotinamide Phosphoribosyltransferase (NAMPT) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors for the Treatment of Drug-Resistant Nonsmall-Cell Lung Cancer. J. Med. Chem. 2023, 66 (1), 1027-1047. (IF: 7.3)
2. Zhang, K.; Ye, K.; Tang, H.; Qi, Z.; Wang, T.; Mao, J.; Zhang, X.; Jiang, S., Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors. J. Med. Chem. 2023, 66 (7), 4378-4416. (IF: 7.3)
3. Ye, K.; Wang, K.; Wang, T.; Tang, H.; Wang, L.; Zhang, W.; Jiang, S.*; Zhang, X.*; Zhang, K.*, Design, Synthesis, Biological Evaluation of Urea Substituted 1,2,5-Oxadiazole-3-carboximidamides as Novel Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors. Eur. J. Med. Chem. 2023, 250, 115217. (IF: 6.7)
4. Tang, H.; Wang, L.; Wang, T.; Yang, J.; Zheng, S.; Tong, J.; Jiang, S.*; Zhang, X.*; Zhang, K.*, Recent Advances of Targeting Nicotinamide Phosphoribosyltransferase (NAMPT) for Cancer Drug Discovery. Eur. J. Med. Chem. 2023, 258, 115607. (IF: 6.7)
5. Zhang, K.#; Wang, K.#; Zhang, X.; Qian, Z.; Zhang, W.; Zheng, X.; Wang, J.; Jiang, Y.; Zhang, W.; Lu, Z.; Hao, H.; Jiang, S., Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of Drug-Resistant Non-small-Cell Lung Cancer. J. Med. Chem. 2022, 65 (11), 7746-7769. (IF: 8.039)
6. Zhang, K.#; Liu, Z.#; Yao, Y.#; Qiu, Y.; Li, F.; Chen, D.; Hamilton, D. J.; Li, Z.; Jiang, S., Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC). J. Med. Chem. 2021, 64 (7), 4020-4033. (IF: 7.446)
7. Zhang, K.; Jiang, S., A new predictive biomarker enables more accurate PD-1 blockade therapy. Cell. Mol. Immunol. 2021, 18 (7), 1624-1625. (IF: 11.530)
8. Zhang, K.; Chen, D.; Ma, K.; Wu, X.; Hao, H.; Jiang, S., NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer. J. Med. Chem. 2018, 61 (16), 6983-7003. (IF: 6.054)